ALX Oncology(NASDAQ) ALXO

ALX Oncology Holdings Inc. makes new medicines to help fight cancer. These drugs help the body find and kill hidden tumor cells. The company aims to help patients with many types of cancer.

A New Way to Target Tumors

• Evorpacept: Lead drug designed to block the "don't eat me" signal that cancer cells use to hide from the immune system.
• ALX2004: Treatment that delivers toxic medicine directly to cancer cells carrying the epidermal growth factor receptor protein.
• Combination Programs: Clinical trials testing evorpacept alongside established cancer drugs to improve their ability to kill tumor cells.

How the Pipeline Is Growing

• Initiated a Phase 2 trial in Jan. 2026 to test evorpacept in patients with breast cancer.
• Entered a new loan agreement with HSBC in June 2026 to provide up to $50.0 million in funding.
• Dosed the first patient in a Phase 1 clinical trial for the new drug candidate ALX2004 in Aug. 2025.
• Partnered with Sanofi in April 2023 to study drug combinations for patients with multiple myeloma.

Designing a Safer Treatment

The company uses a unique drug design to reduce harmful side effects on healthy blood cells. This approach aims to keep treatment safer while still allowing the immune system to attack tumors effectively.

Key Financial Facts

• Net loss was $18.0 million for the three-month period ended June 30, 2026.
• Accumulated deficit reached $758.7 million as of June 30, 2026.
• Cash, cash equivalents, and investments totaled $153.4 million as of June 30, 2026.
• Total capital raised through equity and debt reached $795.0 million from inception through June 30, 2026.

Bottom Line

ALX Oncology has evolved from early research into a clinical-stage developer managing multiple active human trials. Its success depends on validating its specific immune-oncology approach across various solid and blood-based tumors.